63 completed, 7 terminated, 4 withdrawn, 2 recruiting. 79 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 79 | Completed 63, Terminated 7, Withdrawn 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 11 | Completed 6, Recruiting 2, Terminated 2, Withdrawn 1 |
Follow Suspensions: new trials by email Literature Review of Suspensions trials Research Report on Suspensions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS) Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] - Vesico-Ureteral Reflux | Phase 1 | Not yet recruiting | Boston Children's Hospital | 70 | 2027-07-01 | 2026-07-22 |
| A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet - Healthy Volunteers | Phase 1 | Completed | BeOne Medicines | 12 | 2026-06-17 | 2026-10-23 |
| A Study(Phase I)of GS3-007a Dry Suspension in Healthy Chinese Adults GS3-007a for Suspension, Placebo GS3-007a for Suspension - Healthy Adults | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 32 | 2026-01-07 | 2026-11-05 |
| Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions RLF-OD032 100 mg/mL oral suspension, Kuvan 100 MG Powder for Oral Solution - Bioequivalence | Phase 1 | Completed | APR Applied Pharma Research s.a. | 42 | 2025-08-20 | 2026-04-28 |
| A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension, reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension - Healthy Participants | Phase 1 | Completed | Vigonvita Life Sciences | 18 | 2025-08-11 | 2025-11-21 |
| Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule - Eosinophilic Esophagitis | Phase 1 | Completed | AQILION AB | 9 | 2025-06-13 | 2026-06-01 |
| Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy | Phase 1 | Completed | Biocodex | 24 | 2025-06-01 | 2025-09-16 |
| Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects GP681 tablet, GP681 Powder for Oral Suspension - Healthy Participants | Phase 1 | Completed | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 36 | 2024-09-27 | 2025-03-14 |
| A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) PanCytoVir™ 100 mg/mL oral suspension, Probenecid 500 mg - Relative Bioavailability | Phase 1 | Completed | TrippBio, Inc. | 14 | 2024-09-01 | 2024-11-21 |
| Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets Bosentan Dispersible Tablets, Tracleer Tablet for Oral Suspension - Pulmonary Arterial Hypertension | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 32 | 2024-04-21 | 2024-07-03 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension Deuremidevir Hydrobromide for Suspension, Deuremidevir Hydrobromide for Suspension Placebo - Respiratory Syncytial Virus Infections | Phase 1 | Completed | Vigonvita Life Sciences | 24 | 2024-03-27 | 2024-10-01 |
| Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations Lepsiramp, 0.5 Mg/mL Oral Suspension, Fycompa, 0.5 Mg/mL Oral Suspension - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Aya Mohammed Abdel Magid Abdel Hamid | 26 | 2024-03-07 | 2025-08-20 |
| Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants Endotracheopulmonary Instillation, Suspension - Bronchopulmonary Dysplasia | Phase 1 / Phase 2 | Recruiting | EXO Biologics S.A. | 265 | 2023-12-28 | 2024-09-19 |
| A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension Deuremidevir Hydrobromide for Suspension 100mg, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg - Healthy Subjects | Phase 1 | Completed | Vigonvita Life Sciences | 38 | 2023-07-09 | 2024-11-20 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| Biological Response to Platelet-rich Plasma and Corticosteroid Injections Triamcinolone Acetonide 40 mg/ml Inj, Susp, Platelet-rich plasma Inj - Knee Osteoarthritis | Phase 1 / Phase 2 | Terminated | University of Missouri-Columbia | 23 | 2022-12-28 | 2025-06-25 |
| Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] - Tetralogy of Fallot, Pulmonary Insufficiency | Phase 1 / Phase 2 | Completed | Nemours Children's Clinic | 25 | 2022-08-23 | 2026-04-27 |
| QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A) - Metastatic Solid Tumor | Phase 1 | Active not recruiting | ImmunityBio, Inc. | 50 | 2021-06-21 | 2026-11-02 |
| Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension Oseltamivir Phosphate For Oral Suspension/Tamiflu, Oseltamivir Phosphate For Oral Suspension - Healthy Subjects | Phase 1 | Completed | The Affiliated Hospital of Qingdao University | 72 | 2021-05-13 | 2022-03-28 |
| COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule) - Covid19 | Phase 1 | Terminated | ImmunityBio, Inc. | 28 | 2021-02-24 | 2024-10-15 |
Showing 20 of 79. Sign in to see all of them.
Neoplasm Metastasis (4) · Neoplasms (4) · Bacterial Infections (2) · Epilepsy (2) · HIV Infections (2) · Pulmonary Arterial Hypertension (2) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1) · Carcinoma, Renal Cell (1) · Chickenpox (1) · Cystic Fibrosis (1) · Eosinophilic Esophagitis (1) · Epilepsies, Myoclonic (1)
Teva Pharmaceuticals USA (6) · Bayer (5) · Sandoz (5) · Pfizer (4) · ImmunityBio, Inc. (3) · Lakefront Biotherapeutics NV (3) · Vigonvita Life Sciences (3) · Actavis Inc. (2) · AstraZeneca (2) · Aziende Chimiche Riunite Angelini Francesco S.p.A (2) · GlaxoSmithKline (2) · Janssen R&D Ireland (2) · Janssen Research & Development, LLC (2) · Medicines for Malaria Venture (2) · Merck Sharp & Dohme LLC (2)
United States (26) · United Kingdom (10) · Canada (7) · China (7) · Belgium (5) · Brazil (4) · Australia (3) · France (3) · Germany (3) · South Africa (3) · Botswana (2) · India (2) · Italy (2) · Jordan (2) · Netherlands (2)
Magdy L. Shenouda, M.D. (2) · Milko Radicioni, MD (2) · Paul Y. Tam,, MD (2) · Soran Hong, M.D. (2) · Steven Herrmann, M.D. (2) · Xiaojie Wu (2) · Abdullah Hiyari, MD (1) · Alan Jobe, MD, Ph.D (1) · Andrew Wiznia, M.D. (1) · Andrew Wiznia, MD (1)
PMID 15039276, PMID 18587624, PMID 23559821, PMID 24145879, PMID 25035839, PMID 28287489, PMID 29266308, PMID 30527329, PMID 31012984, PMID 31901394, PMID 31972249, PMID 32551947, PMID 32682946, PMID 33340343, PMID 33710976, PMID 34379314, PMID 34505846, PMID 34694878, PMID 34814185, PMID 34817414, PMID 34945097, PMID 35489377, PMID 36045513, PMID 37310224, PMID 38279383, PMID 40560938, PMID 41249688, PMID 42731017
2015 (5), 2014 (2), 2016 (1), 2017 (1), 2018 (1), 2023 (1)